BioPhoundry
Chapel Hill, US · Founded 2024 · Delaware corporation · 1 known investors
Biophoundry develops phage-based technologies for therapeutics, diagnostics, and bio-molecular engineering, including its Phax platform aimed at making phage therapy faster and more affordable. The company focuses on precision antibiotics to address antimicrobial resistance, combining synthetic biology, robotics, and data science.
Founders & leadership
BioPhoundry was founded in 2024 by Rani Brooks.
RB
Rani BrooksinCEO & Co-Founder
SB
Sahan B.W. LiyanagederaNamed on SEC filing
Board
LM
Louis MarlowBoard director
Investors · 1
Reported raises · per SEC filings
Form D private placements$1.1M disclosed across 1 round · 2024
▶$1.1MraisedJan 2025 · 7 investors · BiotechnologyRule 506(b)
▶$1.1MraisedJan 2025 · 7 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Louis MarlowDirector
- Sahan B.W. LiyanagederaExecutive Officer, Director
- Rani T. BrooksExecutive Officer, Director
- Offering amount
- $1.2M
- Amount sold
- $1.1M
- First sale
- Dec 2024
- Incorporated
- Corporation, Delaware, 2024
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- What does BioPhoundry do?
- Biophoundry develops phage-based technologies for therapeutics, diagnostics, and bio-molecular engineering, including its Phax platform aimed at making phage therapy faster and more affordable. The company focuses on precision antibiotics to address antimicrobial resistance, combining synthetic biology, robotics, and data science.
- Who founded BioPhoundry?
- BioPhoundry was founded by Rani Brooks in 2024.
- Who are BioPhoundry's investors?
- BioPhoundry's investors include Creator Fund.
- How much funding has BioPhoundry raised?
- BioPhoundry has disclosed $1.1M raised across 1 round.
- Where is BioPhoundry headquartered?
- BioPhoundry is headquartered in Chapel Hill, US.